Access cutting-edge breast cancer treatment through this clinical trial at a research site in Kansas City. Study-provided care at no cost to qualified participants.
Access breast cancer specialists in Kansas City at no cost
This study follows strict safety protocols and ethical guidelines
All study-related breast cancer treatment provided free
This is a Phase I/II, multi-site, open-label, two-part study designed to evaluate the efficacy, safety, optimized dose and contribution of components of BNT323 in combination with BNT327 in participants with hormone receptor-positive (HR+) or hormone receptor-negative (HR-), Human epidermal growth factor receptor (HER)2-positive, HER2-low (immunohistochemistry \[IHC\] 1+ or IHC 2+/in situ hybridization -), HER2-ultralow (IHC 0, with membrane staining) or HER2-null breast cancer (BC), or triple-n
Sponsor: BioNTech SE
Check if you qualify for this breast cancer clinical trial in Kansas City, MO
If you're searching for breast cancer treatment options in Kansas City, MO, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Kansas City research site is actively enrolling participants for this clinical trial. You'll receive care from experienced breast cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.